|
|
 |
|
Viewing report
|
|
|
|
Biomed Outsourcing Report: Outsourcing Opportunities in China
CanBiotech, Nov 2005, Pages: 19
This report highlights emerging opportunities and challenges associated with outsourcing drug discovery and development activities to China.
Biopharmaceutical Outsourcing in Asia-Pacific discusses market trends in this region as compared to Europe and the United States.
The Life Sciences Industry in China article discusses specific developments in China from changes in the R&D paradigm in China to changes in the healthcare system enabling the development of the biopharmaceutical industry. Specific sectors discussed include: biologics, pharmaceuticals, bioservices, and chemicals.
Emerging Opportunities in China provides an overview of the impact of strong government support, an emerging middle class, low R&D costs, the availability of talented, low-cost human capital and other special resources on the biotechnology, pharmaceutical and outsourcing sectors.
Challenges to Overcome extends the discussion to intellectual property protection, the need for a strong capital market, better regulatory compliance, and the management of language barriers.
Business Models Operating in China compares various business models including partnerships, mergers and acquisitions, joint ventures, and relocation with outsourcing relationships. Managing the outsourcing relationship is also highlighted.
Various company case studies have also been chosen to demonstrate the opportunities available in China and how multinational companies and emerging Chinese companies are taking advantage of these opportunities. Cases include:
AstraZeneca
Danish Centre for Clinical and Basic Research (CCBR)
Dupont
Eli Lilly
Hangzhou Sanofi-Synthelabo Minsheng
Johnson & Johnson
Novartis
Novo Nordisk
Pfizer
Quintiles
Roche
Servier
Beijing University Bioengineering Valley
Crimson Pharmaceutical
Shanghai Genomics
Starvax
WuXi PharmaTech
Zhongguancun Life Science Park
|
|
|
|
